Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Taxol resistance.

S Sangrajrang1, A Fellous

  • 1Research Division, National Cancer Institute, Bangkok, Thailand. sulee@health.moph.go.th

Chemotherapy
|August 31, 2000
PubMed
Summary
This summary is machine-generated.

Tumors can develop resistance to Taxol, a cancer drug, through multiple adaptations. Understanding these mechanisms, particularly changes in microtubules, is crucial for improving cancer treatment strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium.

British journal of cancer·2014
Same author

Detection of BRCA1/2 mutations in breast cancer patients from Thailand and Pakistan.

Clinical genetics·2012
Same author

Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk.

British journal of cancer·2011
Same author

Serum p53 antibodies in correlation to other biological parameters of breast cancer.

Cancer detection and prevention·2003
Same author

SIAH-1 interacts with alpha-tubulin and degrades the kinesin Kid by the proteasome pathway during mitosis.

Oncogene·2001
Same author

The genomic structure of c14orf1 is conserved across eukarya.

Mammalian genome : official journal of the International Mammalian Genome Society·2000
Same journal

Beyond Conventional Monoclonals: Novel Antibody Formats and Derivatives as the Next Frontier in Cancer Therapy.

Chemotherapy·2026
Same journal

Pseudoprogression of a head and neck cutaneous squamous cell carcinoma treated with anti-PD-1 immunotherapy: a case report and review of the literature.

Chemotherapy·2026
Same journal

Clinical Feasibility of Platinum-Based Chemotherapy Followed by Avelumab Maintenance after Enfortumab Vedotin plus Pembrolizumab in Metastatic Urothelial Carcinoma: A case series.

Chemotherapy·2026
Same journal

Efficacy and Safety Study of Different Doses of Linezolid in Combination with Bedaquiline in the Treatment of Drug-Resistant Pulmonary Tuberculosis.

Chemotherapy·2026
Same journal

Can Model-Informed Precision Dosing of Beta-Lactams in Critical Care Improve Clinical Outcomes?

Chemotherapy·2026
Same journal

Expression of Concern.

Chemotherapy·2026
See all related articles

Area of Science:

  • Oncology
  • Pharmacology
  • Cell Biology

Background:

  • Taxol is a widely used chemotherapy agent for various cancers, including breast, ovarian, and lung.
  • Acquired drug resistance in tumors remains a significant challenge in achieving a complete cancer cure.
  • Investigating Taxol resistance mechanisms is vital for developing more effective cancer therapies.

Purpose of the Study:

  • To review current knowledge on Taxol's effects and the development of tumor resistance.
  • To focus on the role of microtubule alterations in Taxol resistance.

Main Methods:

  • Literature review of existing preclinical and clinical data.
  • Analysis of studies focusing on Taxol and drug resistance mechanisms.
  • Emphasis on alterations in microtubules.

Related Experiment Videos

Main Results:

  • Tumor resistance to Taxol is a multifactorial process involving various cellular adaptations.
  • Cellular transport mechanisms play a role in Taxol resistance.
  • Alterations in microtubule dynamics are implicated in Taxol resistance.

Conclusions:

  • Multiple adaptations contribute to acquired Taxol resistance.
  • While cellular transport is important, changes in microtubule transcription and posttranslational modification are key to resistance.
  • Further research into these mechanisms can inform novel therapeutic strategies against Taxol-resistant cancers.